CJC-1295 + ipamorelin combination pen
Five milligrams of the GHRH analogue and ten of the selective secretagogue in one cartridge, the two-route combination at a fixed ratio, for the protocols that run both.
- ISO-certified laboratory
- COA per batch, ≥99% HPLC
- Discreet dispatch within 24 h
- Research use only
Two receptors, one cartridge
The rationale is mechanistic: CJC-1295 works the GHRH receptor, ipamorelin the ghrelin receptor, independent routes to the same endpoint, combined here at 5 mg + 10 mg. A fixed manufactured ratio means every increment delivers both in the same proportion, always. The compound page for the pairing argues that rationale in detail.
That fixedness is the format’s honest trade: protocols needing to vary the ratio need the solo pens instead. For standing two-route work, one cartridge replaces two pens, two needles and one source of sequencing error.
| Compounds | CJC-1295 no DAC + ipamorelin |
| Content | 5 mg + 10 mg, pre-filled |
| Routes | GHRH + ghrelin receptors |
| Ratio | Fixed at manufacture, 1:2 |
| Purity | ≥ 99% (HPLC), both compounds |
| WADA | Both on the prohibited list |
| Category | Research use only |
The certificate reports both compounds, two identity lines, two purity traces, one lot.
Before the CJC-1295 + ipamorelin combination pen reaches the bench
One cartridge, standard rules; the combination changes nothing about storage.
A coherent case, short of proof
The case for combining is easy to state and, so far, hard to prove.
The reasoning behind a cjc-1295 ipamorelin pen is mechanistic and coherent: CJC-1295 drives the GHRH receptor while ipamorelin drives the ghrelin receptor, two independent routes to one endpoint. Combining them at a fixed five-plus-ten-milligram ratio keeps both routes engaged in the same proportion, sound design. What the literature does not yet offer is a controlled trial showing the pair outperforms either compound alone; the rationale is well argued, not demonstrated, and a look through the combined search on PubMed makes that absence plain.
What the combination does deliver, reliably, is consistency. Because the one-to-two proportion is set at manufacture, every increment releases both compounds in that exact ratio, with no chance of the two drifting apart. One cartridge replaces two pens and two needles, closing a gap where sequencing or mismeasurement creeps in. The honest pitch is not a proven edge in outcome but a real gain in repeatability, with the trade that varying the ratio means going back to the solo pens.
One lot, two analytes
A two-compound pen needs a two-compound certificate, one that reads a little longer.
Because two compounds share the cartridge, the certificate has to speak to both, and reading it takes one extra pass. Expect two identity lines: a found mass matching the predicted mass of CJC-1295, and a second matching ipamorelin. Expect two HPLC purity figures too, each at or above ninety-nine percent, because a clean result on one compound says nothing about the other; the COA explainer walks through the same lines for a single-compound document. Both are tied to one lot number, so the paperwork describes precisely the mixture sitting in this pen.
On arrival, the lot number on the pen should match the one heading that dual certificate, a quick check, with twice as much riding on it. For a fixed-ratio combination, an underfilled or off-spec second compound would quietly break the one-to-two proportion the format promises, and only a per-compound trace catches that. A certificate reporting both analytes at or above ninety-nine percent against a single lot is what makes the five-plus-ten-milligram pen a dependable unit rather than two hopeful guesses.
Or run them separately
The solo pens, for protocols that need the ratio in their own hands.
The science behind CJC-1295 + ipamorelin
The combination argued properly, plus its clinical-grade relative.
Questions about the CJC-1295 + ipamorelin combination pen
Combination-specific answers.